Among men with diabetes and hypogonadism, use of testosterone therapy was associated with reductions in acute kidney injury, ...

Mass General Brigham researchers found that continuous glucose monitoring metrics were reflective of a common measure of glucose (hemoglobin A1c) in patients with diabetes, but fell short for people w ...

A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government’s program that gives its Medicare ...

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill.

Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to ...

Weight-loss drugmaker to cut 11.5% of staff 5,000 job cuts in home country of Denmark Expects annual savings of $1.3 billion Will boost performance-based culture, CEO says Shares up 2.1% The ...

Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...

Novo Nordisk (NYSE: NVO)-- the original Ozempic stock-- is getting a boost from a Financial Times report this morning highlighting positive results from two weight loss trials using increased dosages ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

Novo Nordisk is set to lay off roughly 9,000 employees across its global workforce of 78,400 as part of a newly launched restructuring initiative. In a Sept. 10 press release, the Danish ...